New cocktail aims to outsmart pancreatic cancer
NCT ID NCT05721846
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial tests a combination of two immunotherapy drugs (nivolumab and ipilimumab), a vaccine targeting TGFβ-15, and targeted radiation for pancreatic cancer that has not responded to standard treatments. The goal is to see if this mix can safely boost the immune system's attack on tumors. Only 20 participants are enrolled, and the main focus is on side effects and signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab, ipilimumab, TGFβ-15 peptide vaccine, and stereotactic body radiotherapy
What this could lead to
If successful, this could point toward a new combination treatment that helps control pancreatic cancer when other therapies have failed.
What could go wrong
This is a very early Phase 1 trial with only 20 participants, so it is primarily testing safety. The combination may cause significant side effects and may not improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Herlev & Gentofte University Hospital, Denmark
Herlev, 2730, Denmark